-
公开(公告)号：US07132100B2
公开(公告)日：2006-11-07
申请号：US10461904
申请日：2003-06-13
IPC分类号： A61K39/395 , A61K39/40 , A61K39/42 , C07K16/00
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译： 本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，以及很少甚至没有损失 SYNAGIS或其抗原结合片段的生物活性，甚至在长时间的储存期间。 特别地，本发明提供了SYNAGIS或其抗原结合片段的液体制剂，其免疫特异性结合RSV抗原，该制剂基本上不含表面活性剂，无机盐和/或其它常见赋形剂。 此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。
-
公开(公告)号：US07294336B2
公开(公告)日：2007-11-13
申请号：US11362267
申请日：2006-02-24
IPC分类号： A61K39/395 , A61K39/42
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译： 本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，以及很少甚至没有损失 SYNAGIS或其抗原结合片段的生物活性，甚至在长时间的储存期间。 特别地，本发明提供了SYNAGIS或其抗原结合片段的液体制剂，其免疫特异性结合RSV抗原，该制剂基本上不含表面活性剂，无机盐和/或其它常见赋形剂。 此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。
-
公开(公告)号：US20120321616A1
公开(公告)日：2012-12-20
申请号：US13481640
申请日：2012-05-25
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译： 本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，并且极少数或不损失生物 SYNAGIS®或其抗原结合片段的活性，甚至在长时间的储存期间。 特别地，本发明提供了免疫特异性结合RSV抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。 此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。
-
公开(公告)号：US07785592B2
公开(公告)日：2010-08-31
申请号：US11906543
申请日：2007-10-01
IPC分类号： A61K39/395 , A61K39/40 , A61K39/42 , C07K16/00
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译： 本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，并且极少数或不损失生物 SYNAGIS®或其抗原结合片段的活性，甚至在长时间的储存期间。 特别地，本发明提供了免疫特异性结合RSV抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。 此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。
-
公开(公告)号：US20080286270A1
公开(公告)日：2008-11-20
申请号：US11906543
申请日：2007-10-01
IPC分类号： A61K39/395 , A61P11/00
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译： 本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，以及很少甚至没有损失 SYNAGIS或其抗原结合片段的生物活性，甚至在长时间的储存期间。 特别地，本发明提供了SYNAGIS或其抗原结合片段的液体制剂，其免疫特异性结合RSV抗原，该制剂基本上不含表面活性剂，无机盐和/或其它常见赋形剂。 此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。
-
公开(公告)号：US08206951B2
公开(公告)日：2012-06-26
申请号：US13184455
申请日：2011-07-15
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译： 本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，并且极少数或不损失生物 SYNAGIS®或其抗原结合片段的活性甚至在长时间的储存期间。 特别地，本发明提供了免疫特异性结合RSV抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。 此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。
-
公开(公告)号：US20120039876A1
公开(公告)日：2012-02-16
申请号：US13184455
申请日：2011-07-15
IPC分类号： A61K39/395 , B65D85/00 , A61P31/14
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译： 本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，并且极少数或不损失生物 SYNAGIS®或其抗原结合片段的活性甚至在长时间的储存期间。 特别地，本发明提供了免疫特异性结合RSV抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。 此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。
-
公开(公告)号：US08460663B2
公开(公告)日：2013-06-11
申请号：US13481640
申请日：2012-05-25
IPC分类号： A61K39/395 , A61K39/42
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
-
公开(公告)号：US08007793B2
公开(公告)日：2011-08-30
申请号：US12817097
申请日：2010-06-16
IPC分类号： A61K39/395 , A61K39/42
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译： 本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，并且极少数或不损失生物 SYNAGIS®或其抗原结合片段的活性，甚至在长时间的储存期间。 特别地，本发明提供了免疫特异性结合RSV抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。 此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。
-
公开(公告)号：US20110027272A1
公开(公告)日：2011-02-03
申请号：US12817097
申请日：2010-06-16
IPC分类号： A61K39/395 , A61P37/04 , A61P31/12
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译： 本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，并且极少数或不损失生物 SYNAGIS®或其抗原结合片段的活性，甚至在长时间的储存期间。 特别地，本发明提供了免疫特异性结合RSV抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。 此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.053 秒)
